[go: up one dir, main page]

DK3233903T3 - Kimære antigenreceptorer og anvendelsesfremgangsmåder - Google Patents

Kimære antigenreceptorer og anvendelsesfremgangsmåder Download PDF

Info

Publication number
DK3233903T3
DK3233903T3 DK15817277.5T DK15817277T DK3233903T3 DK 3233903 T3 DK3233903 T3 DK 3233903T3 DK 15817277 T DK15817277 T DK 15817277T DK 3233903 T3 DK3233903 T3 DK 3233903T3
Authority
DK
Denmark
Prior art keywords
chimary
antigen receptors
use procedures
procedures
receptors
Prior art date
Application number
DK15817277.5T
Other languages
English (en)
Inventor
Jan Kisielow
Franz-Josef Obermair
Manfred Kopf
Original Assignee
Eth Zuerich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eth Zuerich filed Critical Eth Zuerich
Application granted granted Critical
Publication of DK3233903T3 publication Critical patent/DK3233903T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/10Cellular immunotherapy characterised by the cell type used
    • A61K40/11T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/30Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31Chimeric antigen receptors [CAR]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/30Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32T-cell receptors [TCR]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/40Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41Vertebrate antigens
    • A61K40/42Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/40Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46Viral antigens
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/7051T-cell receptor (TcR)-CD3 complex
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/70539MHC-molecules, e.g. HLA-molecules
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034Isolating an individual clone by screening libraries
    • C12N15/1055Protein x Protein interaction, e.g. two hybrid selection
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0636T lymphocytes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047Cells of the immune system
    • G01N33/505Cells of the immune system involving T-cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/40Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/60Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/61Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00Genetically modified cells
    • C12N2510/02Cells for production
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/24Immunology or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Plant Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK15817277.5T 2014-12-19 2015-12-18 Kimære antigenreceptorer og anvendelsesfremgangsmåder DK3233903T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14199148 2014-12-19
PCT/EP2015/080576 WO2016097334A1 (en) 2014-12-19 2015-12-18 Chimeric antigen receptors and methods of use

Publications (1)

Publication Number Publication Date
DK3233903T3 true DK3233903T3 (da) 2021-02-22

Family

ID=52292645

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15817277.5T DK3233903T3 (da) 2014-12-19 2015-12-18 Kimære antigenreceptorer og anvendelsesfremgangsmåder

Country Status (10)

Country Link
US (3) US10865408B2 (da)
EP (2) EP3233903B1 (da)
JP (1) JP6718450B2 (da)
CN (1) CN107995926B (da)
AU (1) AU2015366305B2 (da)
CA (2) CA3207135A1 (da)
DK (1) DK3233903T3 (da)
ES (2) ES2999411T3 (da)
IL (1) IL252604B (da)
WO (1) WO2016097334A1 (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9511151B2 (en) 2010-11-12 2016-12-06 Uti Limited Partnership Compositions and methods for the prevention and treatment of cancer
EP3065771B1 (en) 2013-11-04 2019-03-20 UTI Limited Partnership Methods and compositions for sustained immunotherapy
EP3233903B1 (en) 2014-12-19 2020-12-09 ETH Zürich Chimeric antigen receptors and methods of use
JP6920211B2 (ja) 2015-05-06 2021-08-18 ユーティーアイ リミテッド パートナーシップ 持続療法用のナノ粒子組成物
WO2017004252A1 (en) * 2015-06-30 2017-01-05 The Arizona Board Of Regents On Behalf Of The University Of Arizona Redirected cells with mhc chimeric receptors and methods of use in immunotherapy
KR20200004807A (ko) * 2017-04-07 2020-01-14 유티아이 리미티드 파트너쉽 나노의약에서 수용체-리간드 상호작용의 효능을 측정하기 위한 어세이
EP3679065A4 (en) 2017-09-06 2021-05-19 California Institute of Technology BIFUNCTIONAL SIGNALING AND RECEPTORS PRESENTING ANTIGENS (SABR)
EP3775903A1 (en) * 2018-04-12 2021-02-17 ETH Zurich Mammalian mhc peptide display as an epitope selection tool for vaccine design
GB2591384B (en) * 2018-08-14 2023-07-26 Univ Texas Single molecule sequencing peptides bound to the major histocompatibility complex
EA202191083A1 (ru) * 2018-10-19 2021-07-23 Етх Цюрих Химерные молекулы
CN111676195A (zh) * 2019-03-11 2020-09-18 北京卡替医疗技术有限公司 一种治疗t细胞肿瘤的ucar免疫细胞
WO2024026452A1 (en) 2022-07-29 2024-02-01 Repertoire Immune Medicines, Inc. T cell epitopes associated with type 1 diabetes

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004501364A (ja) * 2000-05-25 2004-01-15 スノル・モレキュラー・コーポレーション T−細胞レセプター相互作用のモジュレーション
US20080286312A1 (en) * 2002-06-12 2008-11-20 Gavish-Galilee Bio Applications Ltd. Membrane-anchored beta2 microglobulincovalently linked to MHC class I peptide epitopes
BR122020026648B1 (pt) * 2010-09-20 2021-12-07 Biontech Cell & Gene Therapies Gmbh Receptor de células t com especificidade para ny-eso-1, composição farmacêutica compreendendo o mesmo e uso do mesmo
EP3636664A1 (en) * 2012-07-27 2020-04-15 The Board of Trustees of the University of Illinois Engineering t-cell receptors
LT2956175T (lt) * 2013-02-15 2017-12-11 The Regents Of The University Of California Chimerinis antigeno receptorius ir jo panaudojimo būdai
EP3233903B1 (en) 2014-12-19 2020-12-09 ETH Zürich Chimeric antigen receptors and methods of use

Also Published As

Publication number Publication date
US20190345485A1 (en) 2019-11-14
EP3233903B1 (en) 2020-12-09
EP3233903A1 (en) 2017-10-25
IL252604A0 (en) 2017-07-31
CA3207135A1 (en) 2016-06-23
JP2017537642A (ja) 2017-12-21
ES2999411T3 (en) 2025-02-25
US10865408B2 (en) 2020-12-15
US20240425847A1 (en) 2024-12-26
JP6718450B2 (ja) 2020-07-08
AU2015366305A1 (en) 2017-07-27
US11939572B2 (en) 2024-03-26
EP3851450A1 (en) 2021-07-21
CA2969056A1 (en) 2016-06-23
EP3851450B1 (en) 2024-11-27
WO2016097334A1 (en) 2016-06-23
CN107995926B (zh) 2021-07-06
AU2015366305B2 (en) 2020-03-05
IL252604B (en) 2021-02-28
CN107995926A (zh) 2018-05-04
US20210123042A1 (en) 2021-04-29
EP3851450C0 (en) 2024-11-27
CA2969056C (en) 2023-09-05
ES2857052T3 (es) 2021-09-28

Similar Documents

Publication Publication Date Title
IL251970B (en) Anti-cd79b antibodies and methods of use
DK3258951T3 (da) Anti-pvrig antistoffer og fremgangsmåder for anvendelse
DK3514172T3 (da) Claudin-6-specifikke immunoreceptorer og t-celleepitoper
DK3333191T3 (da) Anti-C10ORF54-antistoffer og anvendelser deraf
DK3169703T3 (da) Kimær antigenreceptor og anvendelse deraf
DK3126388T3 (da) Anti-EGFRvIII-antistoffer og anvendelser deraf
DK3280441T3 (da) Anti-sortilin-antistoffer og fremgangsmåder til anvendelse deraf
DK3212255T3 (da) Selvorienterende sprøjte og sprøjtegrænseflade
DK3215532T3 (da) Anti-TIM3-antistoffer og fremgangsmåder til anvendelse
DK3149042T3 (da) PD-L1-antistoffer og anvendelser deraf
DK3210977T3 (da) Hidtil ukendt aminoalkylbenzothiazepinderivat og anvendelse deraf
PL3148579T3 (pl) Przeciwciała anty-gitr i sposoby ich zastosowania
DK3227342T4 (da) Proteinøs heterodimer og anvendelse deraf
DK3116911T3 (da) Anti-mcam-antistoffer og tilhørende fremgangsmåder til anvendelse
DK3309174T3 (da) ANTI-PD-L1-antistoffer og diagnostiske anvendelser deraf
HK1255312A1 (zh) 抗原受體及其用途
DK3215147T3 (da) Neurodæmpende norketamin-forbindelser og fremgangsmåder
DK3218358T3 (da) Ifluorometyl-aminopyridiner og difluorometyl-aminopyrimidiner
DK3233903T3 (da) Kimære antigenreceptorer og anvendelsesfremgangsmåder
DK3015526T3 (da) Hydrofluorolefinbaseret sammensætning og anvendelse deraf
IL263627A (en) Chimeric antigen receptors (cars) specific for muc1 and methods for their use
DK3117777T3 (da) Spredningstomografifremgangsmåde og spredningstomografianordning
DK3161139T3 (da) Tlr-4-specifikke aptamerer og anvendelser heraf
DK3233105T3 (da) Hidtil ukendt kombination og anvendelse
DK3110447T3 (da) Anti-EGFR-antistof og anvendelser heraf